Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Other Non-Current Liabilities (2020 - 2024)

Puma Biotechnology (PBYI) has disclosed Other Non-Current Liabilities for 5 consecutive years, with $121000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Other Non-Current Liabilities changed 0.0% year-over-year to $121000.0, compared with a TTM value of $121000.0 through Dec 2024, changed 0.0%, and an annual FY2024 reading of $121000.0, changed 0.0% over the prior year.
  • Other Non-Current Liabilities was $121000.0 for Q4 2024 at Puma Biotechnology, roughly flat from $121000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $7.5 million in Q1 2023 and bottomed at $37000.0 in Q3 2020.
  • Average Other Non-Current Liabilities over 5 years is $557444.4, with a median of $121000.0 recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities surged 889.29% in 2023, then crashed 98.38% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $233000.0 in 2020, then plummeted by 84.12% to $37000.0 in 2021, then changed by 0.0% to $37000.0 in 2022, then soared by 227.03% to $121000.0 in 2023, then changed by 0.0% to $121000.0 in 2024.
  • Business Quant data shows Other Non-Current Liabilities for PBYI at $121000.0 in Q4 2024, $121000.0 in Q3 2024, and $121000.0 in Q2 2024.